Literature DB >> 3472901

Induction of chromosomal aberrations by the anthracycline antitumor antibiotics N,N-dimethyldaunomycin and aclacinomycin A.

G Steinheider, J Westendorf, H Marquardt.   

Abstract

The clastogenic effect of the anthracycline antitumor antibiotics, N,N-dimethyldaunomycin and aclarcinomycin A, was studied in a murine hemopoietic cell line (Friend leukemia cells). A dose-dependent increase in chromatid lesions, i.e., achromatic lesions, chromatid breaks, chromatid deletions and triradial or quandriradial chromosomal exchange fiqures, was found. It appears that the clastogenicity of N,N-dimethyldaunomycin and aclacinomycin A is lower than that of the classic anthracycline, daunomycin, which is also a potent mutagen and carcinogen. The data demonstrate that the capacity of chemicals to induce point mutations and chromosomal aberrations may not necessarily be correlated: aclacinomycin A is devoid of mutagenic activity in bacterial (Salmonella typh.) and mammalian cell (HGPRT) mutagenesis assays, and is non-carcinogenic in rats. Nevertheless, it was now found to possess clastogenic activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3472901     DOI: 10.1007/BF02143595

Source DB:  PubMed          Journal:  Experientia        ISSN: 0014-4754


  19 in total

1.  DNA complexing antibiotics: daunomycin, adriamycin and their derivatives.

Authors:  A Marco; F Arcamone
Journal:  Arzneimittelforschung       Date:  1975-03

2.  A general mechanism for microsomal activation of quinone anticancer agents to free radicals.

Authors:  N R Bachur; S L Gordon; M V Gee
Journal:  Cancer Res       Date:  1978-06       Impact factor: 12.701

3.  Genetic toxicology of mitomycin C, actinomycins, daunomycin and adriamycin.

Authors:  B K Vig
Journal:  Mutat Res       Date:  1977       Impact factor: 2.433

4.  Structure-activity relationships of anthracyclines relative to effects on macromolecular syntheses.

Authors:  S T Crooke; V H Duvernay; L Galvan; A W Prestayko
Journal:  Mol Pharmacol       Date:  1978-03       Impact factor: 4.436

Review 5.  Current status of Japanese studies with the new anthracycline antibiotic aclacinomycin A.

Authors:  T Oki; T Takeuchi; S Oka; H Umezawa
Journal:  Recent Results Cancer Res       Date:  1980

Review 6.  The anthracycline antineoplastic drugs.

Authors:  R C Young; R F Ozols; C E Myers
Journal:  N Engl J Med       Date:  1981-07-16       Impact factor: 91.245

7.  Mutagenicity of aclacinomycin A and daunomycin derivatives.

Authors:  K Umezawa; M Sawamura; T Matsushima; T Sugimura
Journal:  Cancer Res       Date:  1978-06       Impact factor: 12.701

8.  Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II.

Authors:  K M Tewey; T C Rowe; L Yang; B D Halligan; L F Liu
Journal:  Science       Date:  1984-10-26       Impact factor: 47.728

9.  Tumorigenicity in vivo and induction of mutagenesis and DNA repair in vitro by aclacinomycin A and marcellomycin: structure-activity relationship and predictive value of short-term tests.

Authors:  J Westendorf; H Marquardt; M B Ketkar; U Mohr; H Marquardt
Journal:  Cancer Res       Date:  1983-11       Impact factor: 12.701

10.  Formation of DNA-adducts and induction of DNA-crosslinks and chromosomal aberrations by the new potent anthracycline antitumor antibiotics: morpholinodaunomycin, cyanomorpholinodaunomycin and cyanomorpholinoadriamycin.

Authors:  J Westendorf; G Groth; G Steinheider; H Marquardt
Journal:  Cell Biol Toxicol       Date:  1985-01       Impact factor: 6.691

View more
  1 in total

1.  Growth inhibition of human Tenon's capsule fibroblasts and rabbit dermal fibroblasts with non-carcinogenic N-alkylated anthracyclines.

Authors:  U H Steinhorst; E P Chen; S F Freedman; R Machemer; D L Hatchell
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-06       Impact factor: 3.117

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.